Abstract
Aralia elata was used as therapeutic medicine in oriental courtiers a few hundred years ago. As one important constituent extracted from Aralia elata, Araloside A has been shown to treat gastric ulcers, hepatitis, and arrhythmias. It is not yet known, however, whether Araloside A may induce cell apoptosis in renal cell carcinoma. We therefore examined the antitumor effects of Araloside A on human kidney cancer cell lines GRC-1 and 786-O. We found that Araloside A 1, 3, 10, 30 and 100 μM caused a considerable reduction of cellular viability of GRC-1 1 and 786-O cells in a dose- and time-dependent manner. The number of Tunnel-positive cancer cells was also higher in cells treated with Araloside A than untreated cells. The real-time polymerase chain reaction (PCR) techniques showed that Araloside A was able to increase the expression of bax mRNA and inhibited the expression of bcl-2 mRNA. Conclusively, Araloside A has a remarkably antitumor effect on kidney tumor cells through regulating bax/bcl-2 ratio. © 2011 Academic Journals.
Author supplied keywords
Cite
CITATION STYLE
Yu, L., Jinfeng, L., Zhenhong, L., Yanju, L., Mingna, L., Jing, J., & Wanhai, X. (2011). The antitumor effects of araloside a extracted from the root bark of Aralia elata on human kidney cancer cell lines. African Journal of Pharmacy and Pharmacology, 5(4), 462–467. https://doi.org/10.5897/AJPP10.317
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.